AI assistant
Terns Pharmaceuticals, Inc. — Director's Dealing 2026
Jan 16, 2026
32559_dirs_2026-01-16_c5f10c87-31f8-49dc-91c0-b3fbcebf76f2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Terns Pharmaceuticals, Inc. (TERN)
CIK: 0001831363
Period of Report: 2026-01-14
Reporting Person: Gengos Andrew (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2026-01-14 | Common Stock | A | 68750.00 | $0.00 | Acquired | 101788.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2026-01-14 | Stock Option (Right to Buy) | $37.18 | A | 137500.00 | Acquired | 2036-01-13 | Common Stock (137500.00) | Direct |
Footnotes
F1: Each share is represented by a Restricted Stock Unit ("RSU"). 25% of the RSUs vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/16th of the total number of shares vest quarterly thereafter, such that 100% of the RSUs will be fully vested on the fourth anniversary of the Vesting Commencement Date.
F2: Includes 8,038 shares acquired by the Reporting Person under the Issuer's 2021 Employee Stock Purchase Plan ("ESPP") on November 30, 2025.
F3: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested on the fourth anniversary of the Vesting Commencement Date.